Dr. Reddy's Laboratories (NVO) will launch its off-patent version of Novo Nordisk’s (NVO) blockbuster GLP-1 therapy Ozempic in Canada within the “next few days,” becoming the first to sell a generic ...
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The day has ...
1:24 Health Canada approves generic semaglutide for adults with type 2 diabetes Canada is the first G7 country to authorize generic semaglutide. There are now seven other submissions currently under ...
Health Canada has approved the first generic version of brand-name Ozempic. The department says Canada is the first G7 country to authorize generic semaglutide. The injectable medication is ...
NEW DELHI: A wave of affordable generic versions of Ozempic and Wegovy (semaglutide) has rapidly captured around 20% of the nearly Rs 1,600 crore weight-loss market within days of launch, following ...
LOWERING DRUG COSTS — Bipartisan lawmakers have revived efforts to require Medicare to cover generic drugs — and at least two biosimilars — with patients paying lower costs than for brand-name drugs, ...
The FDA has approved the first generic versions of Farxiga, a drug used to treat Type 2 diabetes and reduce the risk of hospitalization for heart failure. The generic, dapagliflozin, is indicated to ...
The FDA approved the first generics of dapagliflozin (Farxiga) tablets for adults with type 2 diabetes, the agency announced on Tuesday. Generics of the SGLT2 inhibitor are indicated for glycemic ...
March 31 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab has again cut the prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 36% and 48% in India, to fend off ...
In 2026, Novo Nordisk’s patent on semaglutide will expire in several countries, including India and China. Generic-drug makers are poised to flood these markets with inexpensive products. Industry ...
Jamie Dimon is right to be alarmed about our national-security vulnerabilities, especially an overreliance on China and India for generic prescription drugs (“Investments for National Security,” op-ed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results